Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplant
Launched by UNIVERSITY OF PENNSYLVANIA · Feb 24, 2022
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how technology can help new liver transplant recipients take their medications as prescribed. After a liver transplant, it's crucial for patients to follow their medication schedule to keep their new liver healthy and improve their overall well-being. The study will examine how using smartphones, along with support from caregivers and transplant center resources, can make it easier for patients to stick to their treatment plans. The trial is currently recruiting participants from three medical centers.
To be eligible for this trial, participants need to be at least 18 years old, have had a liver transplant within the last three months, and speak either English or Spanish. They should also be living at home and have a smartphone that they are comfortable using for texting or browsing the internet. Care partners, who will support the transplant recipients, must meet similar requirements. Participants can expect to receive support and tools to help them manage their medications better, which could enhance their quality of life and health outcomes after their transplant.
Gender
ALL
Eligibility criteria
- Liver Transplant Recipient Inclusion Criteria:
- • 18 years or older
- • Within 3 months of liver transplant
- • English or Spanish-speaking
- • Home-dwelling\*
- • Patient or care partner owns a smart phone and is comfortable receiving text messages and/or using the internet on the smart phone.
- • \*The definition of "home" includes hotel or short-term housing. Patients who are going to a rehabilitation or skilled nursing facility (SNF) immediately after transplant may still be recruited if the site-PI/Co-I determines they are likely to be discharged to home within 3 months post-transplant.
- Care Partner Inclusion Criteria:
- • 18 years or older
- • English or Spanish speaking
- • Care partner has access to a smart phone and is comfortable receiving text messages and/or using the internet on the smart phone.
- Liver Transplant Recipient Exclusion Criteria:
- • Liver transplant recipient who speaks neither English nor Spanish
- • Any severe uncorrectable vision, hearing, or cognitive impairments that may impede study interviews
- Care Partner Exclusion Criteria:
- • Care partner who speaks neither English nor Spanish
About University Of Pennsylvania
The University of Pennsylvania, a prestigious Ivy League institution located in Philadelphia, is renowned for its commitment to advancing medical research and improving healthcare outcomes. As a clinical trial sponsor, the university leverages its extensive resources, interdisciplinary expertise, and cutting-edge facilities to conduct innovative studies across various therapeutic areas. With a focus on translating scientific discoveries into clinical applications, the University of Pennsylvania fosters collaborations among leading researchers, clinicians, and industry partners, ensuring rigorous trial design and adherence to ethical standards. Through its dedication to excellence in research and education, the university plays a pivotal role in shaping the future of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Miami, Florida, United States
Chicago, Illinois, United States
Patients applied
Trial Officials
Marina Serper, MD
Principal Investigator
University of Pennsylvania
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials